The company agreed to be acquired by funds managed by private equity firms Blackstone and TPG in October 2025. It now says today that the deal — which has a value of up to $79 per share, representing an enterprise value of up to $18.3 billion in total — is now complete.
Yesterday, April 6, 2026, the company said CEO Steve MacMillan would retire upon the completion of the acquisition. Today, the company said it appointed former Baxter head José (Joe) E. Almeida as CEO, effective immediately.
“Hologic is an incredible company with a storied history of innovation and an unparalleled reputation as a leader in women’s health. I am thrilled to be joining at such a pivotal moment,” said Almeida. “With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world.”
More about the new Hologic CEO
Almeida most recently served as chair, president and CEO of Baxter, with his tenure spanning from 2016 to early 2025. In February 2025, he announced his intent to retire from Baxter, effective immediately. He remained with the company in an advisory role through October 2025.
During his time at Baxter, Almeida led a strategic repositioning of the company. Over the past few years, he led the implementation of a new operating model to accelerate innovation and deliver value.
Before Baxter, he served as chair, president and CEO of Covidien until its 2015 acquisition by Medtronic. He also had a senior leadership stint at Tyco Healthcare. Almeida additionally held executive positions at Wilson Greatbatch Technologies, Acufex Microsurgical and Codman & Shurtleff, a division of Johnson & Johnson.
“Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation,” said Ram Jagannath, senior managing director and global head of healthcare at Blackstone.
More about the completion of the go-private transaction
Marlborough, Massachusetts-based Hologic stockholders approved the acquisition on Feb. 5, 2026. The company’s common stock has now ceased trading on the Nasdaq market as a result and will be delisted.
Hologic stockholders stand to receive $76 per share in cash plus a non-tradable contingent value right (CVR). This right enables them receive up to $3 per share in two payments of up to $1.50 each. That amounts to a total consideration of up to $79 per share in cash.
The non-tradable CVR pays out, in part, following achievement of certain global revenue goals for Hologic’s Breast Health business. Those goals pertain to fiscal years 2026 and 2027.
Hologic said the deal included significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide. Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients,” said Alex Albert, Partner at TPG and Co-Head of Healthcare for TPG Capital.
